Gamma-tocopherol therapy for restenosis prevention

1. A drug eluting stent system, comprising: a stent; a tocopherol agent coupled to the stent; wherein said stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.

2. The drug eluting stent system of claim 1 wherein said tocopherol agent is at least one of an agent selected from the group consisting of a des-methyl tocopherol agent, a gamma-tocopherol agent, a delta-tocopherol agent, a phytyl substituted chromanol agent, a gamma-tocotrienol agent, a delta-tocotrienol agent, or a precursor, analog, or derivative thereof.

3. The drug eluting stent system of claim 1 , further comprising: a porous metal carrier matrix; wherein said tocopherol agent is located principally within the porous metal carrier matrix and is adapted to elute therefrom into tissue in contact with said porous metal carrier matrix.

4. The drug eluting stent system of claim 3 , wherein said porous metal carrier matrix comprises an electrochemically deposited matrix.

5. The drug eluting stent system of claim 1 , further comprising a bioactive agent that is different from said tocopherol agent and that is adapted to be delivered into tissue in combination with said tocopherol agent.

6. The drug eluting stent system of claim 5 , wherein said bioactive agent comprises at least one agent selected from the group consisting of sirolimus, tacrolimus, everolimus, ABT-578, paclitaxel, dexamethasone, 17-beta-estradiol, steroid, des-aspartate angiotensin I (DAA-1), angiotensin converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor blocker, tachykinin, sialokinin, apocynin, pleiotrophin, exochelin, an iron chelator, VEGF, heparin, coumadin, clopidogrel, IIb/IIIa inhibitor, nitric oxide, a nitric oxide donor, an eNOS antagonist, a nitric oxide synthesis promoter, a statin, or a precursor, analog, or derivative thereof.